0000000000020074

AUTHOR

Thomas Dörner

showing 8 related works from this author

Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

2011

Introduction: Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkin's lymphoma in a real-life clinical setting. Methods: Patients who received rituximab having shown an inadequate response to standard-of-care had their safety and clinical outcomes data retrospectively analysed as part of the German Registry of Autoimmune…

AdultNephrologyrituximab; autoimmune diseasesmedicine.medical_specialtyHealth StatusImmunologyDrug ResistanceAutoimmune DiseasesDrug HypersensitivityAntibodies Monoclonal Murine-Derived03 medical and health sciences0302 clinical medicineRheumatologyimmune system diseaseshemic and lymphatic diseasesGermanyInternal medicinemedicineHumansImmunology and Allergyddc:610RegistriesRetrospective Studies030203 arthritis & rheumatologyAutoimmune diseasebusiness.industryRetrospective cohort studymedicine.diseaseRheumatology3. Good healthLymphomaPemphigusTreatment OutcomePatient SatisfactionAntirheumatic AgentsRheumatoid arthritisImmunologyRituximabRituximabbusinessImmunosuppressive Agents030217 neurology & neurosurgeryResearch ArticleFollow-Up Studiesmedicine.drugArthritis Research & Therapy
researchProduct

Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk.

2013

Multiple sclerosis (MS) is a genetically complex disease that shares a substantial proportion of risk loci with other autoimmune diseases.1 Along these lines, ANKRD55 , originally implicated in rheumatoid arthritis, was recently reported as a potential novel MS risk gene (rs6859219, p=1.9×10−7).2 Here, we comprehensively validated this effect in independent datasets comprising 8846 newly genotyped subjects from Germany and France as well as 5003 subjects from two genome-wide association studies (GWAS). Upon meta-analysis of all available data (19 686 subjects), ANKRD55 rs6859219 now shows compelling evidence for association with MS at genome-wide significance (OR=1.19, p=3.1×10−11). Our stu…

RFXANKAdultMalemedicine.medical_specialtyMultiple SclerosisLocus (genetics)Genome-wide association studySingle-nucleotide polymorphismBiologyPolymorphism Single NucleotideWhite PeopleMolecular geneticsDatabases GeneticGeneticsmedicineHumansGenetic Predisposition to DiseaseGenetics (clinical)Genetic associationGeneticsMultiple sclerosisMiddle Agedmedicine.diseaseAnkyrin RepeatCase-Control StudiesAnkyrin repeatFemaleCarrier ProteinsGenome-Wide Association StudyJournal of medical genetics
researchProduct

Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition)

2019

All authors: Andrea Cossarizza Hyun‐Dong Chang Andreas Radbruch Andreas Acs Dieter Adam Sabine Adam‐Klages William W. Agace Nima Aghaeepour Mübeccel Akdis Matthieu Allez Larissa Nogueira Almeida Giorgia Alvisi Graham Anderson Immanuel Andrä Francesco Annunziato Achille Anselmo Petra Bacher Cosima T. Baldari Sudipto Bari Vincenzo Barnaba Joana Barros‐Martins Luca Battistini Wolfgang Bauer Sabine Baumgart Nicole Baumgarth Dirk Baumjohann Bianka Baying Mary Bebawy Burkhard Becher Wolfgang Beisker Vladimir Benes Rudi Beyaert Alfonso Blanco Dominic A. Boardman Christian Bogdan Jessica G. Borger Giovanna Borsellino Philip E. Boulais Jolene A. Bradford Dirk Brenner Ryan R. Brinkman Anna E. S. Broo…

0301 basic medicineConsensusImmunologyConsensuCell SeparationBiologyArticleFlow cytometry03 medical and health sciences0302 clinical medicineGuidelines ; Immunology ; Flow cytometryAllergy and ImmunologymedicineCell separationImmunology and AllergyHumansguidelines; flow cytometry; immunologymedicine.diagnostic_testBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.Cell sortingFlow CytometryCell selectionData science3. Good health030104 developmental biologyPhenotypeAllergy and Immunology; Cell Separation; Consensus; Flow Cytometry; Humans; Phenotype[SDV.IMM]Life Sciences [q-bio]/ImmunologyBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.030215 immunologyHumanEuropean journal of immunology
researchProduct

Closing the case ofAPOEin multiple sclerosis: no association with disease risk in over 29 000 subjects: Figure 1

2012

Background Single nucleotide polymorphisms (SNPs) rs429358 (e4) and rs7412 (e2), both invoking changes in the amino-acid sequence of the apolipoprotein E (APOE) gene, have previously been tested for association with multiple sclerosis (MS) risk. However, none of these studies was sufficiently powered to detect modest effect sizes at acceptable type-I error rates. As both SNPs are only imperfectly captured on commonly used microarray genotyping platforms, their evaluation in the context of genome-wide association studies has been hindered until recently. Methods We genotyped 12 740 subjects hitherto not studied for their APOE status, imputed raw genotype data from 8739 subjects from five ind…

GeneticsApolipoprotein E0303 health sciencesCandidate genebusiness.industrySingle-nucleotide polymorphismContext (language use)03 medical and health sciences0302 clinical medicineMeta-analysisImmunologyGenotypeGeneticsMedicinebusinessGenotyping030217 neurology & neurosurgeryGenetics (clinical)030304 developmental biologyGenetic associationJournal of Medical Genetics
researchProduct

A framework for remission in SLE

2017

ObjectivesTreat-to-target recommendations have identified ‘remission’ as a target in systemic lupus erythematosus (SLE), but recognise that there is no universally accepted definition for this. Therefore, we initiated a process to achieve consensus on potential definitions for remission in SLE.MethodsAn international task force of 60 specialists and patient representatives participated in preparatory exercises, a face-to-face meeting and follow-up electronic voting. The level for agreement was set at 90%.ResultsThe task force agreed on eight key statements regarding remission in SLE and three principles to guide the further development of remission definitions:1. Definitions of remission wi…

Genetics and Molecular Biology (all)PediatricsAutoimmune diseasesNEPHRITIS PATIENTSDISEASE-ACTIVITYSeverity of Illness IndexBiochemistryRETROSPECTIVE ANALYSIS0302 clinical medicineQuality of lifePrednisoneAdrenal Cortex HormonesLupus Erythematosus SystemicImmunology and AllergyCHINESE PATIENTS030212 general & internal medicineSYSTEMIC-LUPUS-ERYTHEMATOSUSskin and connective tissue diseasesPREDICTORSOUTCOMESSystemic lupus erythematosusMalalties autoimmunitàriesRemission InductionSYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY; RETROSPECTIVE ANALYSIS; INITIAL VALIDATION; NEPHRITIS PATIENTS; AMERICAN-COLLEGE; CHINESE PATIENTS; RENAL FLARES; PREDICTORS; OUTCOMESSymptom Flare UpConnective tissue diseaseManchester Institute for Collaborative Research on AgeingEstudi de casosOutcomes researchAntibodies AntinuclearDNA/immunologyImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyFarmacologiaResearchInstitutes_Networks_Beacons/MICRAConsensusImmunologyAdrenal Cortex Hormones/therapeutic useAMERICAN-COLLEGELupus Erythematosus Systemic/bloodSystemic Lupus ErythematosusGeneral Biochemistry Genetics and Molecular BiologyMaintenance Chemotherapy03 medical and health sciencesAntimalarialsRheumatologySeverity of illnessmedicineDisease Activity; Outcomes research; Systemic Lupus Erythematosus; Immunology and Allergy; Rheumatology; Immunology; Biochemistry Genetics and Molecular Biology (all)HumansDisease Activity030203 arthritis & rheumatologyPharmacologyAntibodies Antinuclear/bloodLupus erythematosusbusiness.industryTask forceConstruct validityRENAL FLARESComplement System ProteinsDNAINITIAL VALIDATIONDisease Activity; Outcomes research; Systemic Lupus Erythematosusmedicine.diseaseLupus eritematósAntimalarials/therapeutic usePhysical therapyImmunosuppressive Agents/therapeutic useComplement System Proteins/metabolismCase studiesOutcomes researchbusinessAnnals of the Rheumatic Diseases
researchProduct

Genome-wide significant association with seven novel multiple sclerosis risk loci

2015

Objective A recent large-scale study in multiple sclerosis (MS) using the ImmunoChip platform reported on 11 loci that showed suggestive genetic association with MS. Additional data in sufficiently sized and independent data sets are needed to assess whether these loci represent genuine MS risk factors. Methods The lead SNPs of all 11 loci were genotyped in 10 796 MS cases and 10 793 controls from Germany, Spain, France, the Netherlands, Austria and Russia, that were independent from the previously reported cohorts. Association analyses were performed using logistic regression based on an additive model. Summary effect size estimates were calculated using fixed-effect meta-analysis. Results…

GeneticsMultiple SclerosisMultiple sclerosisCase-control studySingle-nucleotide polymorphismLocus (genetics)Genome-wide association studyBiologymedicine.diseaseLogistic regressionPolymorphism Single NucleotideGene FrequencyGenetic LociRisk FactorsCase-Control StudiesGeneticsmedicineHumansGenetic Predisposition to DiseaseAllele frequencyGenetics (clinical)Genome-Wide Association StudyGenetic association
researchProduct

Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) – results from a nationwide cohort in German…

2013

Objective The objective of this article is to evaluate the safety and clinical outcome of rituximab treatment in systemic lupus erythematosus (SLE) patients refractory to standard of care therapy in a real-life setting in Germany. Methods The GRAID registry included patients with different autoimmune diseases who were given off-label treatment with rituximab. Data on safety and clinical response were collected retrospectively. In SLE patients, clinical parameters included tender and swollen joint counts, fatigue, myalgia, general wellbeing, Raynaud’s and the SLEDAI index. Laboratory tests included dsDNA antibody titres, complement factors, hematologic parameters and proteinuria. Finally, th…

AdultMalemyalgiamedicine.medical_specialty610 MedizinCohort StudiesAntibodies Monoclonal Murine-DerivedRheumatologyRefractoryInternal medicineHumansLupus Erythematosus SystemicMedicineIn patientskin and connective tissue diseasesRetrospective Studiesddc:610Proteinuriabusiness.industryOff-Label UseSystemic lupus erythematosus; rituximab; efficacy; safety;Blymphocytes; cohort studiesDiscontinuationCohortPhysical therapyFemaleRituximabmedicine.symptomRituximabbusinessCohort studymedicine.drugLupus
researchProduct

Guidelines for the use of flow cytometry and cell sorting in immunological studies

2017

The marriage between immunology and cytometry is one of the most stable and productive in the recent history of science. A rapid search in PubMed shows that, as of July 2017, using “flow cytometry immunology” as a search term yields more than 68 000 articles, the first of which, interestingly, is not about lymphocytes. It might be stated that, after a short engagement, the exchange of the wedding rings between immunology and cytometry officially occurred when the idea to link fluorochromes to monoclonal antibodies came about. After this, recognizing different types of cells became relatively easy and feasible not only by using a simple fluorescence microscope, but also by a complex and some…

0301 basic medicineT-LymphocytesCell SeparationT cell precursors0302 clinical medicineImmunophenotypingHuman lymphopoiesis[ SDV.IMM ] Life Sciences [q-bio]/ImmunologyImmunology and AllergyNon-U.S. Gov'tImmunologic Techniquemedicine.diagnostic_testResearch Support Non-U.S. Gov'tvirus diseaseshemic and immune systemsFalse Positive ReactionCell sortingFlow Cytometrynatural killer and innate lymphoid cells differentiation3. Good healthResearch Design[SDV.IMM]Life Sciences [q-bio]/ImmunologyHumanQuality Controlmedicine.drug_classImmunologyAnimals; Cell Proliferation; Cell Separation; DNA; False Positive Reactions; Flow Cytometry; Humans; Immunophenotyping; Quality Control; RNA; Research Design; Software; T-Lymphocytes; Guidelines as Topic; Immunologic Techniques; Immunology and Allergy; Immunologychemical and pharmacologic phenomenaGuidelines as TopicComputational biologyBiologyMonoclonal antibodyResearch SupportArticleFlow cytometryImmunophenotypingN.I.H.03 medical and health sciencesImmune systemImmunologic TechniqueResearch Support N.I.H. Extramuralmedicineearly lymphoid progenitorsJournal ArticleAnimalsHumansMass cytometryFalse Positive ReactionsImmunology and Allergy; Immunology; Flow cytometryIMUNOLOGIACell ProliferationAnimalExtramuralB cell ontogenyDNA030104 developmental biologyT-LymphocyteImmunologic TechniquesRNACytometrySoftware030215 immunologyEuropean Journal of Immunology
researchProduct